In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China
Observational study shows ixazomib improves safety and progression-free survival in transplant-ineligible NDMM patients, suggesting a viable treatment strategy.
Key Points
Overall response rate reached 79% after transitioning to ixazomib-based regimens in patients with newly diagnosed multiple myeloma.
Median progression-free survival was 38 months with a 12-month rate of 80% in this patient cohort.
Retrospective analysis utilized NICHE-MM registry data to evaluate efficacy and safety of ixazomib for treatment discontinuation issues.
Findings support ixazomib as a favorable option for transplant-ineligible patients despite comorbidities.